AML is relatively rare - approximately 2,600 people are diagnosed in the UK each year - but as it mainly affects people over 65, prevalence is likely to increase with an ageing population. It is a particularly aggressive cancer, with fewer than a quarter of patients living for five years a...
Improved treatments are clearly needed, and immunotherapies are attractive candidate therapies to explore.There are currently several standard chemotherapeutic treatment schemes for AML, which could be divided into two major groups: (1) cytotoxic chemotherapy ("7+3" or daunorubicin-cytarabine) and (2)...
Targeting MPO expression and enzyme activity sensitizes to AraC treatment by triggering sustained oxidative stress in the high MPO expressing AML cells. Thus the present invention relates to use of myeloperoxidase (MPO) inhibitors for the treatment of chemoresistant acute myeloid leukemia (AML). 展开 ...
AML is the most common type of leukemia in adults, killing more than 10,000 people each year in Canada and the U.S. It starts inblood stem cellsfound in the bone marrow. Chemotherapy has been the first-line treatment for more than 40 years. However, about a third of people do not re...
Purpose: Hyperthermic intraperitoneal chemotherapy (HIPEC) is under continuous evaluation as a potential treatment for ovarian cancer. The purpose of this ... M Muller,M Chérel,PF Dupré,... - 《European Surgical Research》 被引量: 21发表: 2012年 Preoperative chemotherapy and radiation therapy fo...
SAN FRANCISCO — There was a chorus of enthusiasm here at the American Society of Hematology (ASH) 56th Annual Meeting about a first-in-class experimental pill that is taken every day for the treatment of acute myeloid leukemia (AML) and is not cytotoxic. ...
Real-World Outcomes of Oral Azacitidine Maintenance in AML Presented at ASH 2024 AI's Role in Differentiating MDS and Pre-MDS at ASH 2024 Exciting Advances in AML Treatment: Jain on Key Highlights for ASH 2024 A Step Forward in c-Met-Targeted Therapy in NSCLC c-Met as a Biomarker in ...
Chemotherapy serves as a main treatment strategy for acute myeloid leukemia (AML), a neoplastic cancer characterized by the accumulation of aberrant immature cells in the bone marrow (BM). To prevent AML relapse, increasing attention is being paid to leukemia cells that can survive chemotherapy. ...
AI's Role in Differentiating MDS and Pre-MDS at ASH 2024 Exciting Advances in AML Treatment: Jain on Key Highlights for ASH 2024 A Step Forward in c-Met-Targeted Therapy in NSCLC c-Met as a Biomarker in Gastric/GEJ Cancers PD-L1 vs LAG-3 Expression in Non–Small Cell Lung CancerRelate...
VIENNA — The groundbreaking chemotherapy-free combination of arsenic trioxide and all-trans retinoic acid (ATO/ATRA) is effective in the treatment of high-risk acute promyelocytic leukemia (APL) patients but with less toxicity and significantly lower cost than chemotherapy plus ATRA, new research sho...